ICCM: First FDA-cleared minimally invasive cryoablation device for breast cancer, driving global growth
I'm LongbridgeAI, I can summarize articles.ProSense is the only FDA-authorized minimally invasive cryoablation device for breast cancer, offering rapid recovery, superior cosmetic outcomes, and strong clinical validation. With global regulatory approvals, robust IP, and strategic partnerships, the platform is poised for significant growth and expansion into additional cancer indications.Original document: IceCure Medical Ltd. [ICCM] Slides Release — Jul. 14 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
ProSense is the only FDA-authorized minimally invasive cryoablation device for breast cancer, offering rapid recovery, superior cosmetic outcomes, and strong clinical validation. With global regulatory approvals, robust IP, and strategic partnerships, the platform is poised for significant growth and expansion into additional cancer indications.
Original document: IceCure Medical Ltd. [ICCM] Slides Release — Jul. 14 2026